Drug
Pegargiminase clinical trials
Also written ADI-PEG 20 and pegylated arginine deiminase.
- studies test it
- 37
- open now
- 6
- in phase 3
- 4
- first study started
- 2001
Keep track of what changes. Save the pegargiminase studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
36 studies that test it; most in 2014 (6); 1 more planned to start later
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2004 | 1 |
| 2007 | 1 |
| 2011 | 5 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 6 |
| 2015 | 1 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 1 |
| 2022 | 3 |
| 2023 | 5 |
| 2024 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 20
- Phase 2
- 20
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 19 · Other 18
Polaris Group (19) · Washington University School of Medicine (4) · M.D. Anderson Cancer Center (3) · Ludwig Institute for Cancer Research (2) · FDA Office of Orphan Products Development (2) · Memorial Sloan Kettering Cancer Center (1) · University of Miami (1) · Sabine Mueller, MD, PhD (1)
Often tested with
Tested in the same studies.
Gemcitabine (2) · Docetaxel (2) · Carboplatin (2) · Atezolizumab (2) · Regorafenib (1) · GDC-0084 (1) · Dianhydrogalactitol (1) · TSP-1 Activator VT1021 (1)
Studies
Open first, then newest update. How each study uses pegargiminase is read from its arms, and is right about nine times in ten.
Testing it · 37
- A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GlioblastomaRecruitingPhase 2/3Global Coalition for Adaptive ResearchNCT03970447Written as ADI-PEG 20
- Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)RecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06085729Written as ADI-PEG 20
- Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)Not yet recruitingPhase 1/2Sabine Mueller, MD, PhDNCT07389278Written as ADI-PEG 20 (Arginine deiminase pegylated)
- Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular CarcinomaRecruitingPhase 3Polaris GroupNCT05317819Written as ADI-PEG20
- Study of ADI-PEG 20 Versus Placebo in Subjects With NASHRecruitingPhase 2Polaris GroupNCT05842512Written as ADI-PEG20
- Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular CarcinomaRecruitingPhase 2Chang Gung Memorial HospitalNCT06034977Written as ADI-PEG20
- Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid LeukemiaActive, not recruitingPhase 1Polaris GroupNCT05001828Written as ADI-PEG 20
- Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue SarcomaTerminatedPhase 1Washington University School of MedicineNCT05813327Written as ADI PEG20
- ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung CancersTerminatedPhase 1/2Washington University School of MedicineNCT05616624Written as ADI-PEG 20
- Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)TerminatedPhase 3Polaris GroupNCT05712694Written as ADI PEG20
- ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung CancerCompletedPhase 2Washington University School of MedicineNCT03449901Written as pegylated arginine deiminase
- ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma MultiformeActive, not recruitingPhase 2Polaris GroupNCT04587830Written as ADI-PEG 20
- Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal MelanomaCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT03922880Written as ADI PEG20
- ADI-PEG20, Obesity and PrediabetesWithdrawnPhase 2Washington University School of MedicineNCT05829239Written as ADI-PEG20
- A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular CarcinomaWithdrawnPhase 1/2M.D. Anderson Cancer CenterNCT06006286Written as ADI-PEG 20
- Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver CancerWithdrawnPhase 2M.D. Anderson Cancer CenterNCT04965714Written as Pegargiminase
- Study of ADI-PEG 20 in Patients With Advanced MelanomaCompletedPhase 1/2Ludwig Institute for Cancer ResearchNCT00520299Written as ADI PEG 20
- Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung CancerTerminatedPhase 2Ludwig Institute for Cancer ResearchNCT01266018Written as ADI-PEG 20 (Arginine deiminase pegylated)
- Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid CancersTerminatedPhase 1Polaris GroupNCT03254732Written as ADI PEG20
- Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular CarcinomaTerminatedPhase 1/2Polaris GroupNCT02102022Written as ADI-PEG 20 plus modified FOLFOX6
Codes
What other systems call pegargiminase · ClinicalTrials.gg INT004954
- UNII (FDA) 0B7PYQ9YRTPEGARGIMINASEConfirmed FDA, Wikidata
- Wikidata Q110402743pegargiminaseConfirmed FDA, Wikidata
- NCI Thesaurus C91702PegargiminaseOne source FDA
- DrugBank DB06592One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 0B7PYQ9YRT | PEGARGIMINASE | Confirmed FDA, Wikidata |
| Wikidata | Q110402743 | pegargiminase | Confirmed FDA, Wikidata |
| NCI Thesaurus | C91702 | Pegargiminase | One source FDA |
| DrugBank | DB06592 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.